Hauschild, Axel

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 7,720

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 4,496

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,415

Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma

Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 1,389

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

McArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 977

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 640

Deep neural networks are superior to dermatologists in melanoma image classification

Brinker, T. J., Hekler, A., Enk, A. H., Berking, C., Haferkamp, S., Hauschild, A., Weichenthal, M., Klode, J., Schadendorf, D., Holland-Letz, T., et al. (2019) · European Journal of Cancer

Cutaneous Melanoma Detection and ManagementAI in cancer detection

Cited by 415

Epidemiology of invasive cutaneous melanoma

MacKie, R. M., Hauschild, A., & Eggermont, A. M. M. (2009) · Annals of Oncology

Cutaneous Melanoma Detection and ManagementMelanoma and MAPK Pathways

Cited by 405

Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts

Haggenmüller, S., Maron, R. C., Hekler, A., Utikal, J. S., Barata, C., Barnhill, R. L., Beltraminelli, H., Berking, C., Betz-Stablein, B., Blum, A., et al. (2021) · European Journal of Cancer

Cutaneous Melanoma Detection and ManagementAI in cancer detection

Cited by 267

Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks.

Maron, R. C., Weichenthal, M., Utikal, J. S., Hekler, A., Berking, C., Hauschild, A., Enk, A. H., Haferkamp, S., Klode, J., Schadendorf, D., et al. (2019) · European Journal of Cancer

Cutaneous Melanoma Detection and ManagementAI in cancer detection

Cited by 219

Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective

Jutzi, T. B., Krieghoff-Henning, E. I., Holland-Letz, T., Utikal, J. S., Hauschild, A., Schadendorf, D., Sondermann, W., Fröhling, S., Hekler, A., Schmitt, M., et al. (2020) · Frontiers in Medicine

Cutaneous Melanoma Detection and ManagementArtificial Intelligence in Healthcare and Education

Cited by 196

Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark

Brinker, T. J., Hekler, A., Hauschild, A., Berking, C., Schilling, B., Enk, A. H., Haferkamp, S., Karoglan, A., von Kalle, C., Weichenthal, M., et al. (2019) · European Journal of Cancer

Cutaneous Melanoma Detection and ManagementAI in cancer detection

Cited by 157

Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification

Höhn, J., Krieghoff-Henning, E., Jutzi, T. B., von Kalle, C., Utikal, J. S., Meier, F., Gellrich, F. F., Hobelsberger, S., Hauschild, A., Schlager, J. G., et al. (2021) · European Journal of Cancer

AI in cancer detectionCutaneous Melanoma Detection and Management

Cited by 106

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 1: Epidemiology, Genetics and Diagnosis

Lang, B. M., Balermpas, P., Bauer, A., Blum, A., Brölsch, G. F., Dirschka, T., Follmann, M., Frank, J., Frerich, B., Fritz, K., et al. (2019) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft

Nonmelanoma Skin Cancer StudiesCancer and Skin Lesions

Cited by 68

Effectiveness and Tolerability of Ipilimumab: Experiences From 198 Patients Included in a Named-Patient Program in Various Daily-Practice Settings and Multiple Institutions

Eigentler, T. K., Schlaak, M., Hassel, J. C., Loquai, C., Stoffels, I., Gutzmer, R., Pätzold, S., Mohr, P., Keller, U., Starz, H., et al. (2014) · Journal of Immunotherapy

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 23